ST Pharm, a technology-driven RNA CDMO, and Quantoom Biosciences, a specialized RNA technology platform developer, have teamed up to accelerate the development and manufacturing of RNA-based vaccines and therapeutics.
 
This partnership combines their expertise to improve the global supply of critical RNA manufacturing technologies, with a first supply agreement of ST Pharm’s proprietary 5’-capping reagent, SmartCap.
 
By leveraging their respective strengths and expertise, ST Pharm and Quantoom aim to expand their global reach and offer comprehensive solutions to the RNA manufacturing market. This collaboration will enable both companies to utilize their technologies more effectively, accelerating the development and production of innovative RNA-based therapies.
 
This initial collaboration sets the stage for an extended partnership, in which ST Pharm’s proprietary and advanced IVT-based mRNA-LNP platform, including novel capping and formulation reagents, will be made available with Quantoom’s Ntensify and Ncapsulate mRNA production platform. The goal is to create a more robust and flexible RNA manufacturing ecosystem.
 
As a CDMO, ST Pharm will gain valuable insights into Quantoom’s Ntensify mRNA production processes, while Quantoom will benefit from the expanded capabilities enabled by ST Pharm’s unique technologies, resulting in unprecedented levels of manufacturing flexibility for its customers. 
 
“We are excited to partner with Quantoom Biosciences to advance the field of RNA therapeutics,” said Mooje Sung, CEO at ST Pharm. “This collaboration represents a significant step forward in our mission to provide cutting-edge and competitive RNA technologies to the global market. By combining our strengths, we can accelerate the development of life-changing RNA-based therapies.”
 
José Castillo, CEO at Quantoom Biosciences commented: “This collaboration with ST Pharm marks a significant step forward for Quantoom and our NtensifyTMplatform. By securing access to ST Pharm’s unique technologies, we are empowering our clients with unparalleled flexibility and control over their mRNA production processes. This partnership is a testament to our commitment to delivering cutting-edge solutions that drive innovation in the mRNA therapeutics space.”